Veterans Affairs Diabetes Trial (VADT) 

ESC Press Committee's Journals' Digest

Topics: 

Diabetic heart disease

Date : 

07 Jan 2009

In this new "Journals' Digest" feature, Dr Marco Valgimigli of the ESC Press Committee will be providing on a monthly basis two articles of particular interest from a selection of influencial papers such as The New England Journal of Medicine. These will be posted via My ESC News and on the ESC Web Site.

Starting this month, a paper from The New England Journal of Medicine published December 17, 2008 (10.1056/NEJMoa0808431) entitled "Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes"

After the "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation" (ADVANCE) trial and the "Action to Control Cardiovascular Risk in Diabetes" (ACCORD) trial, a third study, the Veterans Affairs Diabetes Trial (VADT) reports no benefit of intensive glucose control over standard care in patients with Type 2 diabetes. 
...........................
Thus authors concluded that intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on the rates of major cardiovascular events, death or microvascular complications. /.../